EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ARHGAP6 Suppresses Breast Cancer Tumor Growth by Promoting Ferroptosis via RhoA-ROCK1-p38 MAPK Signaling

Xiaoqing Chen, Jing Zhu, Xiangzhi Li, Jintao Chen, Zhisheng Zhou, Xulong Fan, Ruijian Liang, Haiyan Liu, Dajiang Zhu

Frontiers in Bioscience-Landmark · 12.01.2024 · 29 (1)

DOI: 10.31083/j.fbl2901006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 12.01.2024. Verfasst von Xiaoqing Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medicine, Southern Medical University Affiliated Maternal & Child Health Hospital of Foshan, 528000 Foshan, Guangdong, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Ferroptosis, GTPase-Activating Proteins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovation Project of Women and Children medical research center affiliated to Foshan Institute of Fetal Medicine, Foundation of Bureau of Science and Technology of Foshan, Medical Research Project of Foshan Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ferroptosis, a distinct iron-dependent form of regulated cell death, is induced by severe lipid peroxidation due to reactive oxygen species (ROS) generation. Breast cancer patient survival is correlated with the tumor-suppressing properties of Rho guanosine triphosphatase hydrolase enzyme (GTPase)-activating protein 6 (ARHGAP6). This study investigates the impact and mechanisms of ARHGAP6 on ferroptosis in breast cancer.

Methods

Using quantitative RT-PCR, Western blotting, and immunofluorescence staining, ARHGAP6 expression was detected in a gene expression dataset, cancer tissue samples, and cells. ARHGAP6 was overexpressed or silenced in breast cancer cell lines. Cell proliferation was measured using 5-ethynyl-2-deoxyuridine (EdU) assay, and cell death rate was determined using LDH cytotoxicity assay. As indicators of ferroptosis, Fe2+ ion content, lipid ROS, glutathione peroxidase 4 (GPX4), ChaC glutathione specific gamma-glutamylcyclotransferase 1 (CHAC1), prostaglandin-endoperoxide synthase 2 (PTGS2), solute carrier family 7 member 11 (SLC7A11), and acyl-CoA synthetase long chain family member 4 (ACSL4) levels were evaluated.

Results

ARHGAP6 was obviously downregulated in cancer tissues and cells. ARHGAP6 overexpression decreased cell proliferation, elevated cell death and lipid ROS, decreased GPX4 and SLC7A11, increased PTGS2, ACSL4, and CHAC1, and inhibited RhoA/ROCK1 and p38 MAPK signaling in cancer cells. ARHGAP6 knockdown exerted opposite effects to those of ARHGAP6 overexpression. p38 signaling suppression reversed the effect of ARHGAP6 knockdown on ferroptosis, while RhoA/ROCK1 signaling inhibition compromised the effect of ARHGAP6 on p38 MAPK signaling. In mice models, ARHGAP6 together with the ferroptosis inducer RSL3 cooperatively enhanced ferroptosis and inhibited tumor growth of cancer cells. ARHGAP6 mRNA level was positively correlated with that of ferroptosis indicators in tumor tissues.

Conclusions

This study revealed that ARHGAP6 inhibited tumor growth of breast cancer by inducing ferroptosis via RhoA/ROCK1/p38 MAPK signaling. Integrating ARHGAP6 with ferroptosis-inducing agents may be a promising therapeutic strategy for breast cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsFerroptosisGTPase-Activating ProteinsAnimalsFemaleHumansMiceCyclooxygenase 2Lipidsp38 Mitogen-Activated Protein KinasesReactive Oxygen Speciesrho-Associated Kinases

Stichwörter der Autor:innen

ARHGAP6breast cancerferroptosisp38 MAPK

Substanzen

ARHGAP6 protein, humanCyclooxygenase 2GTPase-Activating ProteinsLipidsp38 Mitogen-Activated Protein KinasesReactive Oxygen Speciesrho-Associated KinasesROCK1 protein, human

Autor:innen und Institutionen

  • Department of Breast Medicine, Southern Medical University Affiliated Maternal & Child Health Hospital of Foshan, 528000 Foshan, Guangdong, China.

Förderung

  • Innovation Project of Women and Children medical research center affiliated to Foshan Institute of Fetal Medicine
  • Foundation of Bureau of Science and Technology of Foshan
  • Medical Research Project of Foshan Health Commission

Zitieren

APA

Chen, X., Zhu, J., Li, X., Chen, J., Zhou, Z., Fan, X., Liang, R., Liu, H., & Zhu, D. (2024). ARHGAP6 Suppresses Breast Cancer Tumor Growth by Promoting Ferroptosis via RhoA-ROCK1-p38 MAPK Signaling. Frontiers in Bioscience-Landmark, 29(1). https://doi.org/10.31083/j.fbl2901006

Vancouver

Chen X, Zhu J, Li X, Chen J, Zhou Z, Fan X, et al. ARHGAP6 Suppresses Breast Cancer Tumor Growth by Promoting Ferroptosis via RhoA-ROCK1-p38 MAPK Signaling. Frontiers in Bioscience-Landmark. 2024;29(1). doi:10.31083/j.fbl2901006

BibTeX
@article{Chen2024,
  author = {Chen, Xiaoqing and Zhu, Jing and Li, Xiangzhi and Chen, Jintao and Zhou, Zhisheng and Fan, Xulong and Liang, Ruijian and Liu, Haiyan and Zhu, Dajiang},
  title = {ARHGAP6 Suppresses Breast Cancer Tumor Growth by Promoting Ferroptosis via RhoA-ROCK1-p38 MAPK Signaling},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2024},
  volume = {29},
  number = {1},
  doi = {10.31083/j.fbl2901006}
}
Kostenlos starten →